Biotech & Life Sciences, with structure-aware discipline
Therapeutics, diagnostics and life sciences platforms with clinical, regulatory and IP-centric portfolio management.
Biotech and life sciences investing depends on clinical, regulatory and IP milestones rather than commercial metrics. Portfolios need clinical trial tracking, regulatory pathway modelling, IP portfolio management and value inflection modelling that accounts for readouts, approvals and licensing outcomes. Reuben AI provides an operating layer purpose-built for biotech and life sciences investors with clinical, regulatory and IP-centric portfolio management.
Why this asset class needs a different operating model
Clinical milestones drive value. Trial phase progression, readouts and approvals are the primary value inflection points. Structured tracking is essential.
Regulatory pathway matters. FDA, EMA, PMDA and other regulator pathways determine timeline and probability of success. Pathway modelling drives underwriting.
IP position defines defensibility. Composition of matter, method-of-use and formulation patents each contribute to defensibility. IP portfolio tracking is first-class.
Licensing is a common exit. Licensing deals and structured collaborations often exceed IPO or acquisition value. Deal-structure modelling matters.
How Reuben AI covers it
Clinical trial tracking
Trial phase, patient enrolment, readouts and endpoints tracked structurally per portfolio company.
Regulatory pathway modelling
FDA, EMA, PMDA and other pathways modelled with probability of success and timeline milestones.
IP portfolio management
Composition of matter, method-of-use and formulation patents tracked structurally with expiry and geographic coverage.
Licensing and structured deal modelling
Licensing deals, milestones, royalties and structured collaborations modelled with returns waterfall.
LP reporting for biotech
LP reporting with clinical progress, regulatory status, IP position and structured deal outcomes.
Sub-asset overlays inside Biotech & Life Sciences
Biotech & Life Sciences carries 9 sub-asset overlays in the Reuben AI rubric registry: Therapeutics preclinical, Therapeutics clinical stage, Platform biotech, Diagnostics, Medical devices, Contract research and manufacturing, Animal health, Genomics and sequencing and Drug delivery. Those overlays are part of the 314 sub-asset overlays the platform maintains across 56 of its 68 native asset classes.
An overlay never reweights the parent rubric. It adds the extra scoring criteria, risk flags, document types and key term fields that only apply to that slice, so a therapeutics preclinical deal and a drug delivery deal are both scored on the shared biotech & Life Sciences rubric while each is still asked the questions specific to its structure. That is what keeps deals inside one asset class comparable to each other and to the rest of the portfolio.
Selecting an overlay at intake changes what the platform expects: the document checklist, the extraction schema for key terms, and the flags raised when a term sits outside the range the rest of your biotech & Life Sciences book has accepted. Nothing is retrofitted later by hand.
- Therapeutics preclinical
- Therapeutics clinical stage
- Platform biotech
- Diagnostics
- Medical devices
- Contract research and manufacturing
- Animal health
- Genomics and sequencing
- Drug delivery
The diligence record a biotech & Life Sciences deal produces
Every biotech & Life Sciences opportunity that moves through Reuben AI leaves a structured record rather than a folder of documents and a memo. The rubric score is stored with the criteria that produced it, each extracted key term is stored with the clause and page it came from, and every flag is stored with the reason it fired and who cleared it.
The practical effect is that the investment committee paper, the LP report line and the audit trail are all reading the same underlying record. When an LP asks in year three why a biotech & Life Sciences position was underwritten the way it was, the answer is retrieved, not reconstructed.
- Rubric score with the criteria and weights that produced it
- Key terms extracted with a clause-level source reference
- Risk flags with the trigger, the owner and the resolution
- Comparison against prior deals in the same asset class
- Investment committee pack generated from the stored record
- An immutable trail of who changed what and when
What this means for fund operations
Biotech & Life Sciences sits as a core allocation for VC and Growth Equity mandates, and is adjacent or opportunistic for 7 of the other fund types the platform serves.
That matters operationally because most funds do not hold biotech & Life Sciences alone. The moment a portfolio spans more than one asset class, comparability becomes the constraint: a position scored on a bespoke biotech & Life Sciences spreadsheet cannot be ranked against a position scored somewhere else. Running biotech & Life Sciences on the same rubric engine as the rest of the book removes that break.
Reporting inherits the same property. Portfolio monitoring, valuation cadence, capital account movement and LP reporting all draw from the single stored record, so a biotech & Life Sciences position appears in the quarterly pack on the same basis as every other holding, with the same evidence behind it.
Relevance by fund type
VC
Core
PE
Opportunistic
Private Credit
Opportunistic
Growth Equity
Core
Hedge Fund
Adjacent
Infrastructure
Niche
Family Office
Adjacent
Emerging
Adjacent
CVC
Adjacent
Institutional
Adjacent
Asset classes held alongside this one
Pre-IPO
Late-stage private placements in companies preparing for public listing, with lockup and registration tracking.
Climate Tech
Venture and growth capital into decarbonisation with emissions accounting, Article 9 reporting and impact evidence.
Digital Transformation
Thematic allocations into legacy-industry digitisation with operational KPI and software adoption telemetry.
Fintech & Regtech
Banking, payments, capital markets and compliance technology with licensing and unit-economics tracking.
Foodtech & Alt Protein
Cultivated meat, fermentation, plant-based and food supply-chain innovation with regulatory and scale-up milestone tracking.
Agtech & Precision Agriculture
Precision agriculture, farm robotics, biologicals and ag-data platforms with adoption and field trial evidence tracking.
Full coverage across all 68 native asset classes is listed on the coverage page.
Related solutions
Common questions
Are clinical trial milestones tracked?
Yes. Trial phase, patient enrolment, readouts and endpoints are tracked structurally per portfolio company.
Which regulatory pathways are covered?
FDA, EMA, PMDA and other major regulators are modelled with probability of success and timeline milestones per indication.
How are licensing deals modelled?
Licensing deals with upfront, milestone and royalty structures are modelled with full returns waterfall.
How many sub-asset overlays does Biotech & Life Sciences have?
9: Therapeutics preclinical, Therapeutics clinical stage, Platform biotech, Diagnostics, Medical devices, Contract research and manufacturing, Animal health, Genomics and sequencing and Drug delivery. They sit within the 314 overlays the platform maintains across 56 of its 68 native asset classes.
Which fund types treat biotech & Life Sciences as core?
VC and Growth Equity. Relevance for every other fund type is shown in the relevance grid on this page, graded as core, adjacent, opportunistic or niche.
Can biotech & Life Sciences be compared against other asset classes in the same portfolio?
Yes. Every asset class runs on the same rubric engine, so scores, flags and key terms are stored in a common structure. Positions across different asset classes are ranked and reported on the same basis.
See Biotech & Life Sciences in Reuben AI
Book a demo to walk through deal flow, diligence and reporting tailored to this asset class.